

Boston Scientific Schedule Of Major Presentations At The American College Of Cardiology 2013

NATICK, Mass., March 4, 2013 [/PRNewswire/](#) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 62nd Annual Scientific Session of the American College of Cardiology which takes place March 9-11 in San Francisco, California. The clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.

Schedule of Events

All programs are Pacific Standard Time with events held at the Moscone Center.

Saturday, March 9

- **PREVAIL Late Breaking Clinical Trial Results:** David R. Holmes Jr., M.D., Mayo Clinic, Rochester, Minn., will present the acute procedural safety results of the PREVAIL clinical trial that evaluates the WATCHMAN® left atrial appendage closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy. PREVAIL is a confirmatory trial on the safety and efficacy of the WATCHMAN device. Results will be presented at 9:10 a.m. in South, Esplanade Ballroom.
- **PLATINUM Vessel Straightening Analysis:** Jeffrey J. Popma, M.D., Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass., will present the results of the PLATINUM vessel straightening analysis, designed to evaluate the impact of stent design on native vessel distortion following coronary artery stenting in severely angulated lesions. Results will be presented at 10:00 a.m. in the Poster Session area, Expo North.

Sunday, March 10

- **PLATINUM Three-Year Clinical Trial Results:** Ian T. Meredith, M.B.B.S., Ph.D. MonashHeart, Southern Health, Monash Medical Center, Clayton, Victoria, Australia, will present the three-year data of the PLATINUM Workhorse clinical trial. Two year follow-up of this trial confirmed the safety and efficacy of the platinum chromium PROMUS Element™ Plus Stent System, which uses the combination of the market-leading everolimus drug and fluorinated copolymer. Results will be presented at 8:15 a.m. in West, Room 2001.

Monday, March 11

- **REPRISE I Feasibility Study:** Ian T. Meredith, M.B.B.S., Ph.D. MonashHeart, Southern Health, Monash Medical Center, Clayton, Victoria, Australia, will present six-month study results of the differentiated second generation Lotus Aortic Valve Replacement System. REPRISE I was designed as a feasibility study with a primary endpoint of clinical procedural success. Results will be presented at 9:15 a.m. in West, Room 2009.

Conference attendees are invited to visit Boston Scientific and "Technologies that transform tomorrow and Products that perform today" at booth N5933.

The WATCHMAN and Lotus devices are investigational devices and not available for sale in the United States.

All clinical data results are embargoed until the time of each scientific presentation.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on [Twitter](#) and [Facebook](#).

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials and impact of their results, product

performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:

Steven Campanini
508-652-5740 (office)
Global Media Relations
Boston Scientific Corporation
media@bsci.com

Michael Campbell
508-650-8023 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com

SOURCE Boston Scientific Corporation

<https://news.bostonscientific.com/2013-03-04-Boston-Scientific-Schedule-Of-Major-Presentations-At-The-American-College-Of-Cardiology-2013>